Real-World data on glofitamab shows promise for Tough-to-Treat lymphoma
NCT ID NCT06994169
First seen Jan 16, 2026 · Last updated Apr 29, 2026 · Updated 14 times
Summary
This study looks back at the medical records of 250 adults with large B-cell lymphoma who received the drug Glofitamab through a special access program in France. The goal is to see how well the drug works and what side effects occur in everyday practice, especially in patients whose cancer came back after CAR-T cell therapy. Researchers will track tumor shrinkage and survival over about 9 months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LARGE B-CELL LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CH Victor Dupouy
RECRUITINGArgenteuil, 95100, France
Contact
-
CH d'Avignon - Hôpital Henri Dufaut
RECRUITINGAvignon, 84000, France
Contact
-
CH de Dunkerque
RECRUITINGDunkirk, France
Contact
-
CH de Mulhouse Sud Alsace
RECRUITINGMulhouse, 68070, France
Contact
-
CH de Quimper Cornouaille
RECRUITINGQuimper, 29107, France
Contact
-
CH de la Côte Basque
RECRUITINGBayonne, France
Contact
-
CHR d'Orléans
RECRUITINGOrléans, France
Contact
-
CHRU Besançon - Hôpital Minjoz
RECRUITINGBesançon, France
Contact
-
CHRU de LILLE - Claude Huriez
RECRUITINGLille, France
Contact
-
CHRU de Nancy - Hôpital de Brabois
RECRUITINGVandœuvre-lès-Nancy, France
Contact
-
CHU Lyon Sud
RECRUITINGPierre-Bénite, France
Contact
-
CHU de Dijon - Hôpital le Bocage
RECRUITINGDijon, 21000, France
Contact
-
CHU de Grenoble - Hôpital Albert Michallon
RECRUITINGLa Tronche, France
Contact
-
CHU de Poitiers - Hôpital de La Milétrie
RECRUITINGPoitiers, France
Contact
-
CHU de Rennes - Hôpital de Pontchaillou
RECRUITINGRennes, France
Contact
-
CHU de Strasbourg
RECRUITINGStrasbourg, France
Contact
-
Centre Léon Bérard
RECRUITINGLyon, 69373, France
Contact
-
Ch de Bretagne Atlantique
RECRUITINGVannes, France
Contact
-
Chu Bretonneau
RECRUITINGTours, France
Contact
-
Chu de Bordeaux - Hopital Haut-Leveque
RECRUITINGPessac, France
Contact
-
Clinique du Pont de Chaume
RECRUITINGMontauban, France
Contact
-
Gustave Roussy Cancer Campus Grand Paris
RECRUITINGVillejuif, France
Contact
-
Hopital D'Instruction Des Armees Percy
RECRUITINGClamart, 92141, France
Contact
-
Hopital Henri Mondor
RECRUITINGCréteil, France
Contact
-
Hopital Saint Vincent-de-Paul
RECRUITINGLille, France
Contact
-
Hopital Saint-Louis
RECRUITINGParis, France
Contact
-
Hôpital de Libourne
RECRUITINGLibourne, France
Contact
-
INSTITUT PAOLI CALMETTES - Service Hématologie
RECRUITINGMarseille, France
Contact
-
Institut Curie - Site Saint-Cloud
RECRUITINGSaint-Cloud, France
Contact
-
Institut Universitaire du Cancer de Toulouse - Oncopole
RECRUITINGToulouse, France
Contact
Conditions
Explore the condition pages connected to this study.